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The Hematopoietic Stem Cell Regulatory Gene Latexin
Has Tumor-Suppressive Properties in Malignant
Melanoma
Viswanathan Muthusamy1, Sanjay Premi2, Cara Soper3, James Platt1 and Marcus Bosenberg1
Despite recent advancements in therapy, melanoma remains a highly lethal skin cancer. A better understanding
of the genetic and epigenetic changes responsible for melanoma formation and progression could result in the
development of more effective treatments. Advanced melanomas are known to exhibit widespread promoter
region CpG island methylation leading to the inactivation of key tumor suppressor genes. Meta-analyses of
relevant microarray data sets revealed the hematopoietic stem cell regulator gene latexin (LXN) to be commonly
downregulated in approximately 50% of melanomas. The CpG island in the promoter region of LXN was
almost universally hypermethylated in melanoma cell lines and tumors, and treatment of the cell lines with
the demethylating drug 5-aza-20-deoxycytidine resulted in increased LXN expression. In this paper, we
demonstrate that the exogenous expression of LXN in melanoma cell lines results in a significant inhibition
of tumor cell proliferation. In addition, we show that the increased expression of LXN in these lines correlates
with reduction in the expression levels of stem cell transcription factors OCT4, NANOG, SOX2, KLF4, and MYCN,
indicating that LXN may exert its tumor-suppressive function by altering the stem cell-like properties of
melanoma cells.
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INTRODUCTION
Melanoma is the most deadly form of skin cancer. About
76,250 new cases and 9,180 deaths due to melanoma are
expected in 2012 in the United States alone (Cancer Facts and
Figures 2012, American Cancer Society, http://www.cancer.
org). A number of genetic alterations have been identified in
melanoma development and progression. Genes regulating the
mitogen-activated protein kinase pathway are frequently
mutated in melanoma, including activating mutations of the
BRAF serine/threonine kinase and NRAS, which are encoun-
tered in 50% and 25% of melanomas, respectively (Davies
et al., 2002; Edlundh-Rose et al., 2006; Krauthammer et al.,
2012). The CDKN2A locus at 9p21, which encodes two tumor
suppressor genes p16INK4A and p14ARF, is altered in the
majority of sporadic melanomas and about 40% of familial
melanomas (Aitken et al., 1999; Goldstein et al., 2007).
Recently, exome sequencing has revealed several novel
mutations in genes influencing key melanoma signaling
pathways. These mutations are generally rare but nevertheless
thought to have an important role in driving the melanomas.
Mutations of PPP6C, a serine/threonine phosphatase, and
RAC1, a GTPase, were recently reported in 9–12% of melano-
mas (Hodis et al., 2012; Krauthammer et al., 2012). TRRAP, a
component of an important complex possessing histone acetyl-
transferase activity, is mutated in 4% of melanomas (Wei et al.,
2011). Mutations of MEK1 and MEK2 kinases were found in 8%
of melanomas (Nikolaev et al., 2012). PREX2, a negative
regulator of PTEN tumor suppressor gene, was found to be
altered in 14% of melanomas (Berger et al., 2012).
Epigenetic silencing has been known to have a key role
in inactivating tumor suppressors in melanoma and other
cancers. Several studies have demonstrated that increased
promoter region CpG island hypermethylation invariably
occurs in advanced melanomas. A high incidence of promoter
methylation of several loci in melanoma has been previously
observed, including RARB (70%), RASSF1A (55%), PYCARD
(50%), and MGMT (34%; Guan et al., 2003; Spugnardi et al.,
2003; Hoon et al., 2004). Using a global screen for promoter
hypermethylation in melanoma, we previously identified
several genes that are hypermethylated in the vast majority
of melanomas, including QPCT, CYP1B1, and LXN, which
were methylated in greater than 95% of melanoma tumor
samples (Muthusamy et al., 2006).
Latexin (LXN) was originally identified as a neural marker of
the lateral neocortex in the developing mammalian brain
(Arimatsu, 1994; Hatanaka et al., 1994) and was later
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described as the human homolog of endogenous inhibitor of
rat carboxypeptidase A (Liu et al., 2000). In humans, LXN
inhibits the carboxypeptidase (CPA4), a gene known to have a
role in the development of aggressive prostate cancer
phenotypes (Pallares et al., 2005). LXN shows significant
homology at the protein level to TIG1, a tumor suppressor
silenced by hypermethylation in several types of cancer (Jing
et al., 2002; Youssef et al., 2004). Knockout studies in murine
models showed LXN to be a modulator of sensory perception,
particularly in the transmission of pain sensation (Bai et al.,
2004; Jin et al., 2006). Liang and colleagues identified the
LXN locus as the primary determinant of hematopoetic stem
cell (HSC) frequency variation between two inbred mouse
strains. Exogenous expression of LXN in the hematopoietic
compartment showed it to be a negative regulator of
hematopoietic stem cell numbers (Liang et al., 2007). A
tumor regulatory role for LXN was suggested where LXN
may function as a ‘‘tumor progenitor gene’’ controlling tumor
stem cells (Liang and Van Zant, 2008). More recently, LXN
was described to be silenced by methylation and function as a
tumor suppressor in human gastric cancers and lymphomas (Li
et al., 2011; Liu et al., 2012). In this paper, we present
evidence that LXN is downregulated in 450% of melanomas
by promoter hypermethylation, has a tumor-suppressive role,
and negatively regulates the expression of tumor-sustaining
stem cell factors.
RESULTS
LXN expression is downregulated in melanoma
In a previous screen for methylation changes in melanomas,
we found reduced expression of LXN compared with primary
cultured melanocytes that was linked to promoter hyper-
methylation (Muthusamy et al., 2006). To increase the
power of our observations and examine LXN status in
benign nevi, we performed a meta-analysis for LXN
expression in publicly available Gene Expression Omnibus
(GEO) expression data sets and other published microarray
data comprising a total of: 18 melanocytes, 59 melanoma cell
lines, 7 normal skin, 18 benign nevi, and 133 melanoma
samples GDS1965, (Hoek et al., 2004), GDS1375, (Talantov
et al., 2005), GDS3012, (Muthusamy et al., 2006; Koga et al.,
2009), and GSE29377 (Avery-Kiejda et al., 2011). We found
that LXN expression was generally lower in melanoma tissue
samples and cell lines relative to normal skin, benign nevi,
and melanocytes (Figure 1a). We used a classification system
based on expression compared with median signal intensity of
normal controls in each of the experiments, to stratify LXN
expression as explained in the methods section. LXN was
detectably expressed in all nonmalignant samples included in
the study. Relatively high levels of LXN expression was seen in
greater than 70% of melanocytes and normal skin samples and
in over 50% of benign nevi samples (Figure 1b). In contrast,
LXN expression ranged from absent to very low in 48% of the
melanoma cell lines and 24% of melanoma tissue samples in
the meta-analysis (Figure 1b).
Quantitative PCR for LXN expression performed in a
validation set consisting of a panel of melanoma cell lines
and microdissected melanoma biopsy samples closely
reflected the meta-analysis observations. LXN mRNA levels
were decreased in all melanoma cell lines (n¼10) studied, as
well as in a majority (74%, n¼19) of uncultured melanoma
tissue samples, compared with primary melanocytes
(Figure 2a). Analysis of LXN protein expression levels by
western blotting showed absent to low expression of LXN in
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Figure 1. Expression analysis of latexin (LXN) in human melanoma and
melanocytes. (a) Meta-analysis of Gene Expression Omnibus (GEO) data sets
showing LXN mRNA expression in normal cells—melanocytes, normal skin,
benign nevi; and malignant cells—melanoma cell lines and tumors. Each dot
represents the ratio of the expression signal of an individual sample to the
median signal of normal samples in that experiment. (b) Stratified levels of LXN
expression in normal and malignant states.
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Figure 2. Validation of reduced latexin (LXN) expression in melanoma. (a)
Quantitative PCR analysis of LXN expression in melanoma cell lines and tumor
tissue samples. (b) Western blot analysis for LXN protein expression in
melanoma cell lines. (c) Western blot analysis showing LXN protein expression
in tumor samples compared with cultured melanocytes.
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melanoma cell lines relative to melanocytes, and correlated
with mRNA expression levels (Figure 2b). Analysis of protein
expression by western blotting in the tumor samples showed
slightly reduced levels of LXN compared with melanocytes
(Figure 2c). As immunohistochemical analysis can resolve the
expression at a cellular level, we analyzed the expression
patterns of LXN in melanoma patient samples in The Human
Protein Atlas (http://www.proteinatlas.org) database. Interpre-
tation of the immunohistochemistry data was performed on
human melanoma biopsy samples (n¼ 11) that were stained
using the validated LXN antibody (HPA 014179, Sigma). A
heterogeneous pattern of staining was observed in most of the
tumor sections. Nine out of a total of eleven samples showed
weak to absent LXN expression, and of the two remaining
samples one sample showed moderate levels and the other
showed strong staining (Supplementary Table S2 online).
Promoter hypermethylation is frequently encountered in
melanoma and is associated with silencing of LXN
We had previously found that LXN was generally reexpressed
in melanoma cell lines upon treatment with the methylation
inhibitor 5-aza-20-deoxycytidine. This was also observed in
another study that included several other melanoma lines
(Muthusamy et al., 2006, unpublished data) (Figure 3a). We
evaluated promoter hypermethylation of LXN in blood sam-
ples, melanocytes, congenital nevi, melanoma cell lines, and
in melanomas. We found that promoter region of LXN was
methylated in 95% of the melanoma cell lines and 94% of
melanoma tumor samples and was unmethylated in normal
melanocytes and in congenital nevi (Figure 3b; Supplementary
Table S3 online). To explore the possibility of the use of
methylated LXN as a tumor biomarker of circulating tumor
cells in blood of melanoma patients, we evaluated the LXN
promoter methylation status in peripheral blood lymphocyte
DNA samples from normal healthy volunteers (n¼ 55), which
revealed a complete absence of methylation (Supplementary
Figure S1 online).
LXN has tumor-suppressive properties in melanoma
To establish the tumor-suppressive function of LXN, we stably
transfected two human melanoma cell lines: (1) MelJuSo,
which has no detectable LXN protein expression, and (2)
C8161, which expresses LXN protein at levels similar to those
of melanocytes. In the LXN-transfected and selected clones, the
expression levels of LXN was observed to be generally lower
than melanocytes, suggesting that high LXN expression was
growth suppressive. Further, LXN expression decreased with
continued culture of the clonal lines in vitro, eventually
reverting to baseline levels of the parental line (data not shown).
Cell proliferation assays demonstrated that LXN-transfected
stable clones of both MelJuSo and C8161 resulted in slower
growth compared with vector-transfected controls (Figure 4).
Colony formation assays showed that LXN-expressing Mel-
JuSo clones formed only about half the number of colonies as
LXN-nonexpressing controls. The colonies formed by LXN-
expressing cells were generally small and comprised less than
100 cells, whereas vector control cells typically formed
colonies that were 10 times larger (Figure 5a). To assess the
potential of the transfected cells to grow in an anchorage-
independent manner, we performed colony formation assays
in soft agar. LXN-expressing MelJuSo cells formed colonies
less frequently and were smaller in size compared with vector
controls (Figure 5b). In xenograft experiments on immunode-
ficient mice, significantly smaller tumors were present, follow-
ing injection of LXN-expressing clones compared with vector
controls. LXN-nonexpressing vector clones formed tumors
earlier than two of the three LXN clones and grew to form
tumors that were on average greater than 2-fold larger in size
(Figure 5c).
The ability to form nonadherent cellular spheres is thought
to be a distinctive attribute of stem cells (Galli et al., 2004;
Fang et al., 2005). Under nonadherent culture conditions, we
observed a reduction in both number and size of melanoma
spheres formed by two out of the three LXN-expressing clones
compared with the vector-transfected controls (Figure 6a).
Regulation of stem cell-associated transcription factors by LXN
Analysis of microarray expression data from 27 melanoma cell
lines showed that levels of stem cell transcription factors
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Figure 3. Promoter region hypermethylation leads to the silencing of latexin
(LXN) in melanoma. (a) Analysis of microarray data from two previous
experiments showing restoration of LXN expression in melanoma cell lines
upon treatment with methylation reversing drug 5-aza-20-deoxycytidine
(5-aza-dc). Study1: dark blue (Muthusamy et al., 2006); Study2: light blue
(unpublished data). (b) Sanger bisulfite sequencing of the LXN gene promoter
CpG island in melanocytes, melanoma cell lines, and tumor samples. CpG
positions are indicated by circles in scale to their location in the promoter
region. Clear circles indicate the absence of methylation, and filled circles
represent methylated cytosine. The numbers at the top indicate the distance
from the transcription start site. Stars indicate that the methylation status of
these samples was described previously (Muthusamy et al., 2006).
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OCT4, NANOG, SOX2, KLF4, and MYC were generally
higher in melanoma cells compared with melanocytes.
(Figure 6b; Muthusamy et al., 2006; Koga et al., 2009).
Given the role of Lxn in the negative regulation of HSCs in
mice, we sought to determine whether tumor-suppressor
function of LXN is correlated to these stem cell factors in
melanoma. Quantitative PCR-based expression analysis of
LXN-transfected stable clonal lines of MelJuSo and C8161
showed that restoration of LXN expression correlated with a
general reduction in the expression of all the stem cell factors,
with a significant decrease in the expression of KLF4 and MYC
transcription factors in both the cell lines compared with their
respective vector controls (Figure 6c).
DISCUSSION
LXN was originally identified as a marker of neurons in the
lateral cortex region of the developing mammalian brain
(Arimatsu, 1994). A diverse range of biological functions has
since been attributed to LXN, including modulation of sensory
perception (Bai et al., 2004), pain transmission (Jin et al., 2006),
regulation of inflammatory responses (Aagaard et al., 2005),
inhibition of carboxypeptidase CPA4 (Pallares et al., 2005), and
regulation of HSCs (Liang et al., 2007). Lxn regulation of stem
cell function raised the possibility of the modulation of tumor
cells with self-renewing capabilities (Liang et al., 2007; Liang
and Van Zant, 2008). A tumor suppressor role for LXN has
been recently shown in human gastric carcinomas and
lymphomas (Li et al., 2011; Liu et al., 2012).
Here we provide evidence that LXN expression is low to
absent in the majority of human melanomas and that it has a
tumor-suppressive function. Robust expression levels in nor-
mal cells and frequent loss in melanoma make LXN a potential
biomarker for the discrimination of melanoma cells from their
benign counterparts. As many benign nevi express melano-
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Figure 4. Inhibition of cell proliferation by exogenous expression of latexin
(LXN). (a) Quantitative PCR and western blot analysis of LXN expression in the
vector and LXN-transfected clones of the MelJuSo melanoma cell line.
(b) Growth curves showing differences in the proliferation of LXN-transfected
and vector control lines of MelJuSo. (c) Quantitative PCR and western blot
analysis of LXN expression in the vector and LXN-transfected clones of C8161
melanoma cell line. (d) Growth curves showing difference in the proliferation
of LXN-transfected and vector control lines of C8161. Note that LXN
protein was expressed in the original parental line, which is reflected in the
vector-transfected controls.
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cytic levels of LXN, its expression can potentially add to
increased specificity of multiple marker-based approaches
that have been described for improved distinction of nevi
from melanoma (Kashani-Sabet et al., 2009; Zhang and Li,
2012). Near-universal methylation in tumors compared with
the absence of methylation in normal cells also make
detection of LXN methylation in body fluids a plausible
approach for early diagnosis of melanoma, use as a
surrogate to estimate tumor burden, or for detection of
remnant tumor cells post surgery, or treatment with drug or
immune-based therapies. The observation that the exogenous
expression of LXN in the melanoma cell line C8161, which
already expresses LXN at levels seen in melanocytes, still
resulted in the strong inhibition of proliferation suggesting that
the elevation of LXN protein expression above the steady-state
level for cancer cells may not be compatible with rapid
growth. This observation raises the possibility of the
development of cancer therapeutics that can upregulate
the expression of LXN protein in tumor cells, regardless of
the status of their default LXN expression. These drugs could
potentially include the DNA methyltransferase inhibitors, as
we and several others have shown that the promoter region of
the LXN gene is commonly hypermethylated in tumor cells
compared with their normal counterparts, and that 5-aza-20-
deoxycytidine can restore the expression of LXN in tumor cell
lines. Phase I trials using 5-aza-20-deoxycytidine have already
been carried out in combination with other standard of care
melanoma treatments. Clinically objective responses in the
form of complete and partial remission have been observed in
a small subset of patients receiving such therapy (Gollob et al.,
2006; Tawbi et al., 2012).
The term ‘‘cancer stem cells’’ has been proposed for the
subpopulations of cells that are able to maintain the growth of
malignant tumors. Cancer stem cells frequently share cell
surface markers with their normal stem cell counterparts, are
capable of self-renewal, and may give rise to a more
differentiated progeny (Lapidot et al., 1994; Bonnet and
Dick, 1997; Lobo et al., 2007). Lxn was shown to be the
primary quantitative trait locus negatively regulating HSC
numbers in mice (Liang et al., 2007). Mouse strains express-
ing low levels of Lxn were found to have significantly more
HSCs than their counterparts expressing relatively high levels.
Enhancement of Lxn expression by retroviral transfection in
bone marrow cells led to a reduction in HSC frequency in
mice (Liang et al., 2007). Additional evidence of LXN
involvement in stem cell regulation is provided by studies
showing that RNA interference -mediated depletion of the
stem cell factors OCT4 and NANOG, which are required to
maintain pluripotency and self-renewal (Nichols et al., 1998;
Chambers et al., 2003), leads to a concomitant increase in
LXN levels (GSE4189; Loh et al., 2006). It has recently been
demonstrated that transcription factors including OCT4,
NANOG, SOX2, KLF4, and MYC are central mediators of
stem cell self-renewal and pluripotency (Takahashi and
Yamanaka, 2006; Okita et al., 2007; Wernig et al., 2007).
The combined expression of these factors has been shown to
convert somatic cells into induced pluripotent stem cells that
have a morphology, epigenetic profile, and gene expression
signature similar to embryonic stem cells (Takahashi and
Yamanaka, 2006; Okita et al., 2007; Wernig et al., 2007).
We found elevated levels of OCT4, NANOG, SOX2, and
KLF4 in several melanoma cell lines, including MelJuSo and
C8161 relative to primary melanocytes, and that the
expression levels of the most oncogenic factors, KLF4 and
MYC, are associated with the exogenous expression of LXN.
These findings raise the possibility that LXN might function as
a tumor suppressor by regulating cancer progenitor cells with
stem-like properties.
MATERIALS AND METHODS
Blood, tissue specimens, primary cells, and cell lines
The melanoma tissue and blood samples were obtained in accor-
dance with the Institutional Review Board-approved protocols at the
Yale University (New Haven, CT), University of Vermont (Burlington,
VT), Memorial Sloan-Kettering Cancer Center (New York, NY), and
Dana-Farber Cancer Institute (Boston, MA). Patient consent was not
required because the material was de-identified. All of the melanoma
samples were derived from lymph nodes or cutaneous metastases.
Frozen tumor specimens in OCT were macrodissected to 80% purity
of tumor cells guided by examination of a hematoxylin and eosin
slide by a pathologist (MB).
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Figure 6. Changes in tumor progenitor properties upon reexpression of
latexin (LXN). (a) In vitro melanoma sphere formation assay in nonadherent
conditions showing reduced numbers of spheres in LXN-transfected clones
compared with vector (pTRE)-transfected controls. Data are shown for a
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experiments. (b) The expression of stem cell transcription factors in melanoma
cell lines compared with melanocytes derived from microarray expression
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clones of MelJuSo and C8161 compared with parental lines.
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All the cell lines used in the study were grown in Dulbecco’s
modified Eagle’s medium-F12 medium (Invitrogen, Grand Island, NY)
supplemented with 5% fetal bovine serum and nonessential amino
acids (Invitrogen). Primary cultured human foreskin melanocytes
were grown in Medium 254 supplemented with human melanocyte
growth serum (Cascade Biologics, Portland, OR). LXN expression
constructs were generated by reverse transcriptase–PCR amplification
of full-length coding sequence from primary melanocytes and sub-
cloning into the pTRE-tight expression vector (Clontech, Mountain
View, CA). The inserts were verified by Sanger sequencing to ensure
an absence of reverse transcription-introduced mutations. Stable
transfectants were produced by transfection with Lipofectamine
(Invitrogen) and selected by growth in media containing 800mg ml 1
G418 (Invitrogen). Single colonies were ring cloned, expanded, and
analyzed for transgene expression using reverse transcriptase–
quantitative PCR.
Bisulfite sequencing and quantitative RT-PCR
DNA was isolated from cells and tissues using standard phenol–
chloroform extraction. Bisulfite modification was performed as pre-
viously described (Herman et al., 1996) using genomic DNA from
normal blood, melanocytes, melanoma cell lines, and melanoma
tissue samples. PCR reactions to interrogate LXN promoter CpG
island were carried out using 50 ng of bisulfite-modified DNA in a
30ml volume with a 0.2mM primers (forward—50-GGATGTAGG
GAGTTTGGGTT-30 and reverse—50-TTCCATTCCRAATAAACAAT
AAC-30). PCR products were purified using the Qiaquick Gel
Extraction kit (Qiagen, Valencia, CA) and directly sequenced on the
ABI 3100-Avant automated DNA sequencer. Real-time quantitative
PCR for LXN was performed by using 2.5ml of 100-fold diluted cDNA
template and 0.2mM LXN-specific primers in a 25ml PCR reaction,
using JumpStart SYBR green kit (Sigma, St Louis, MO) according to
the manufacturer’s instructions with an ABI 7700 (Applied Biosys-
tems, Foster City, CA). Real-time quantitative PCR for stem cell-
associated transcription factors OCT4, NANOG, SOX2, KLF4, and
MYC was performed using 2.0ml of 10-fold diluted cDNA template
and 0.2mM gene-specific primers in a 20ml fast PCR reaction using
FastStart Universal SYBR green mix (Roche, Indianapolis, IN) in an
ABI StepOne Plus Real-time PCR system. All the real-time reactions
including that for LXN and the stem cell-associated transcription
factors were performed in duplicate. CT values obtained were
normalized to glyceraldehyde-3-phosphate dehydrogenase levels
and quantification was performed using the comparative CT
method. All primer sequences are provided in Supplementary
Table S1 online.
Western blotting
Western blotting experiments were conducted by separation of 20mg
of cell lysate per sample on SDS-PAGE, transfer to Immobilon-P
membranes (Millipore, Billerica, MA), blocking with phosphate-
buffered saline containing 0.2% Tween-20 and 5% nonfat milk,
and incubation with LXN antibodies (N-17: sc-47090; Santa Cruz
Biotechnology). Following washes and incubation with peroxidase-
conjugated donkey anti-goat secondary antibodies (Abcam, Cam-
bridge, MA), ECL-Advance detection system (Amersham Biosciences,
Pittsburgh, PA) was used for chemiluminescent detection. The blots
were stripped and re-probed with actin antibodies (AC-40, Sigma) to
confirm equal protein loading.
In vitro proliferation assays, clonogenic assays, and colony
formation in soft agar
In vitro growth curve assays were performed as previously described
(Muthusamy et al., 2006). In brief, three replicates of 10,000 cells
each of the vector and LXN-transfected cells were seeded in six-well
cell culture plates for each time point. The cells were trypsinized,
diluted, and counted on a flow cytometer (Colter) at 24-hour
intervals, starting at 0 hour and ending at 120 hours. Colony
formation assays were performed by plating three replicates of
1,000 cells of the vector and LXN-transfected cells in six-well cell
culture plates and evaluating colony formation at 2 weeks. For the
soft agar assay, a base layer of 0.5% agar in growth media was
prepared in six-well tissue culture plates. An upper layer was formed
by adding 500 cells into 0.35% agarose in growth media. Samples
were plated in duplicate and were prepared at the same time to
correct for effects on plating efficiency. Colonies were allowed to
grow for 4 weeks within the soft agar. Staining for both colony
formation assays and soft agar assays was carried out by adding
0.005% crystal violet in 20% methanol, followed by washing with
distilled water and destaining with 100% methanol.
Melanoma sphere formation assay
LXN-transfected cells and vector controls were seeded at 1,000 cells
per well of a 24-well Ultra-Low Attachment Costar tissue culture plate
(Costar, Corning, NY). Melanoma spheres were allowed to form
without any disturbance for 2 weeks and quantified. The cells were
also seeded in duplicate in a 24-well tissue culture dish, the cells
were allowed to attach, and then stained with 40-6-diamidino-2-
phenylindole to ensure equal seeding of the cells.
Tumor formation in nude mice
For the xenograft assay, two vector control clones and three LXN-
transfected clones were pelleted, resuspended in cold Hank’s
balanced salt solution, and 0.5 106 cells in 100ml were injected
subcutaneously into the flank skin of nude mice. Two mice were
assigned per condition and each mouse was injected twice, one
injection to each flank. Tumor dimensions (maximum length and
width) were measured every week and the mice were killed at
10 weeks after injection.
Statistics
The results of the proliferation assay, clonogenic assays, melanoma
sphere formation assays, and xenografting assays were analyzed for
statistical significance using the Student’s t-test.
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